Gilead Sciences (Nasdaq: GILD) announced that the European Commission has granted marketing authorization for Zydelig (idelalisib), 150 mg tablets, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE